Q-omics provides the consensus-scored CCDC178 profile across patient tissues and cancer cell-line models. CCDC178 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC178 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, CCDC178 RNA expression shows 15,202 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where CCDC178 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC178 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC178 survival associations across molecular data types. CCDC178 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC178 RNA expression–survival associations across cancer types. High CCDC178 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, PAAD, UCS, KIRP and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC178 RNA expression.
This table summarizes CCDC178 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC178. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC178 shows lower tumor expression in KIRP, KIRC, BLCA, THCA, HNSC and COAD. The KIRP box plot shows higher CCDC178 RNA expression in normal versus tumor tissue (log2 FC = −1.904, t-test p < 0.001).
This table shows molecular features associated with CCDC178 in patient tissues and cancer cell lines. In patient samples, CCDC178 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC178 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
